Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.
Market
Infectious Diseases
Location
Seattle,
WA,
USA
Coinvestors
Adams Street Partners, NanoDimension, Qiming Venture Partners, Sanofi Ventures